TSE:MDNA Medicenna Therapeutics Q2 2026 Earnings Report C$0.40 -0.01 (-2.41%) As of 03:59 PM Eastern ProfileEarnings History Medicenna Therapeutics EPS ResultsActual EPS-C$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMedicenna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicenna Therapeutics Announcement DetailsQuarterQ2 2026Date11/13/2025TimeAfter Market ClosesConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Medicenna Therapeutics Earnings HeadlinesMedicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine PlatformsJune 11, 2026 | globenewswire.comMedicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026June 3, 2026 | globenewswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 23 at 1:00 AM | Porter & Company (Ad)Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead ProgramsMay 28, 2026 | globenewswire.comMedicenna Therapeutics Corp.May 25, 2026 | marketwatch.comMedicenna Announces the Filing of its Prospectus Supplement and Investment Term SheetMay 22, 2026 | globenewswire.comSee More Medicenna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email. Email Address About Medicenna TherapeuticsMedicenna Therapeutics (TSE:MDNA) Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.View Medicenna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Sudden Plunge May Be an AI Buying ChanceLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break OutBuy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They? Upcoming Earnings Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
